Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

VentiRx Pharmaceuticals Inc.

This article was originally published in Start Up

Executive Summary

VentiRx Pharmaceuticals Inc. has been working since 2007 to develop TLR8 agonists for allergic rhinitis and cancer, while considering how they might also be used in other indications. The company reported positive data from Phase I clinical trials in both areas within the past year, but has recently decided to move forward in cancer only.
Advertisement

Related Content

Celgene To Collaborate With VentiRx On TRL8 Receptor Agonist For Cancer
Upheaval And Opportunity Reshape The Oncology Market
Tocagen Inc.
Start-Up Previews
Polaris Group
Tesaro Inc.
Cyterix Pharmaceuticals Inc.
Tragara Pharmaceuticals Inc.
Upheaval And Opportunity Reshape The Oncology Market
Start-Up Previews

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC092155

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel